Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development

doi:10.4251/wjgo.v15.i10.1717

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3844)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series.

Item

Count

PDF

WORD

HTML

2254

Figures (1-9)

220

Sum=2576

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

183

Download

515

Sum=698

Publishing Process of This Article

Item

Count

Browse

113

Download

350

Sum=463

Oct 15, 2023 (publication date) through Nov 23, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1717-1738
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1717

Full Size Figure Download Figure

Figure 3 Identification of tumor antigens associated with hepatocellular carcinoma prognosis. A: Venn diagram of mutated genes, amplified genes, highly expressed genes, and prognostic genes; B-N: Kaplan-Meier curves showing that high expression of AURKA (B), CCNB1 (C), CDC25C (D), CDK1 (E), KIF2C (F), KPNA2 (G), MCM3 (H), NEK2 (I), PES1 (J), PPM1G (K), PRC1 (L), PTTG1 (M), and TRIP13 (N) indicates a worse overall survival in hepatocellular carcinoma patients. AMP: Amplification; HR: Hazard ratio; RFS: Recurrence-free survival.

Citation: Lu TL, Li CL, Gong YQ, Hou FT, Chen CW. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development. World J Gastrointest Oncol 2023; 15(10): 1717-1738
URL: https://www.wjgnet.com/1948-5204/full/v15/i10/1717.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i10.1717